Ensuring Affordable Access to Healthcare

Access to healthcare is at the core of what we do. Our programs focus on the most important public health needs and can cover a person’s entire experience: from prevention and detection, to early diagnosis and access, to treatment and care.

We have a proud, rich history of supporting societies around the world. To ensure this tradition continues, we launched Sanofi Global Health in April 2021. An autonomous, non-profit unit designed for long-term sustainability, Sanofi Global Health aims to sell products at affordable prices–or donate when necessary–and to support local capacity building. It will serve 40 low- and middle-income countries with an initial list of 30 essential medicines, including treatments for cardiovascular diseases, diabetes, cancer, malaria, and tuberculosis.

Dr Ariany Widiastuty examines Salim at Penyengat Olak Public Health Center in Jambi Province, Indonesia

Targeting non-communicable diseases 

An integral focus of the Sanofi Global Health is non-communicable diseases (NCDs), which are responsible for 41 million deaths every year.1 Of these, 37% are premature deaths affecting people between the ages of 30 and 69, with cardiovascular diseases claiming more lives annually than any other disease.2 NCDs disproportionately affect people in low- and middle-income countries, where more than 85% of premature deaths occur. 

In sub-Saharan Africa, where most people live far from health facilities that offer targeted prevention and intervention, cardiovascular diseases are a leading cause of both morbidity and mortality and claim more lives every year than HIV/AIDS, neonatal disorders, and malaria combined.3,4,5 This is the only region in the world where mortality due to cardiovascular disease is on the rise.6 The financial burden of these diseases poses a new public health crisis that has paralyzed many health systems.7,8 

That’s why we launched a multi-year, multi-country partnership between Sanofi Global Health and Medtronic Labs to expand access to healthcare for underserved patients living with hypertension and diabetes. Starting in Tanzania and Sierra Leone, we’ll work together to leverage digital health approaches and local health system partners to improve disease awareness, diagnosis, and management of diabetes and hypertension. We’re also combatting NCDs in Cambodia, in partnership with both Medtronic Labs and reach52, which delivers health services through its proprietary access health platform and products.

These programs will serve as a model for future community-focused chronic disease management programs, designed to support health systems as they build towards universal health coverage and the United Nations Sustainable Development Goals.

Supporting people with rare diseases

Even in countries with developed healthcare systems, patients may encounter difficulties accessing treatment for many reasons. Some people may have limited or no health insurance, or their country’s public health system does not reimburse the price of treatments. To help ensure no one falls through the gaps, we also work with health authorities and patient groups to supply free treatment to people with lysosomal disorders. First launched in the US in 1991, the Charitable Access Program now supports more than 3,300 people with five types of lysosomal storage disorders in over 70 countries across six continents. It has been extended to new countries, following approvals in Mozambique and Senegal.

In 2021, a total of 110,000 treatment vials were donated, enabling more than 1,000 patients with rare diseases to receive treatment.

Find out more

People diagnosed with rare diseases often feel isolated and responsible for explaining their disease to their own physicians. Sanofi scientist Danielle Dong explains the importance of disease registries in bringing communities together, supporting patients, doctors, and scientists alike

Developing a global access plan

Affordability is not the only barrier to access for many people. So too is the speed at which we launch new medicines into our different markets. To address this problem, our goal is to develop a global access plan for all new products, making them available in all chosen markets within two years of launch. This bold ambition will ensure that millions more people receive timely treatment and thousands of lives are saved. In 2021, we launched a pilot global access plan using one of our new treatments to develop a blueprint for the future.

 

1 World Health Organization (2021). Non-communicable diseases. Published 13 April 2021; accessed 3 March 2022.

2 University of Oxford (2019). Our World in Data: Causes of Death. Accessed 3 March 2022.

3 World Health Organization (2021). Non-communicable diseases. Published 13 April 2021; accessed 3 March 2022.

4 WHO Bulletin Volume 96(3);  2018 March 1.

5 University of Oxford (2019). Our World in Data: Causes of Death. Accessed 3 March 2022.

6 Amegah KA (2018) Tackling the Growing Burden of Cardiovascular Diseases in Sub-Saharan Africa. Circulation 138: 2449-2451. doi: 10.1161/CIRCULATIONAHA.118.037367.

7 Institute for Health Metrics and Evaluation (2018) Findings from the Global Burden of Disease Study 2017. Lancet Global Burden of Disease

8  Harvard School of Public Health and World Economic Forum (2018) The Global Economic Burden of Non-Communicable Diseases. Report.

Our pricing principles in the US

Too many Americans still struggle to pay for their medicines and treatments due to out-of-pocket drug costs. Our Pricing Principles, launched in 2017, aim to promote a culture of transparency that is adopted not only in our industry, but across healthcare. The results can be seen in our 2022 Pricing Principles report that shows the average net price of our US medicines portfolio has declined for the sixth year in a row.

Read our 2022 Pricing Principles Report